Case GI SPORE

这一案例Gl孢子提案提供了一个胃肠道恶性肿瘤的前沿专门研究计划，重点是结直肠癌，并额外关注食管腺癌。这一全面的计划建立在病例综合癌症中心的资源基础上，提出了4个翻译研究项目，为G1癌症患者带来新的分子进步。一系列4个核心资源支持这些研究项目，并为G1癌症的翻译研究建立了强大的规划基础设施。我们进一步开发了一个全面的基础设施，用于从整个病例癌症中心的基础科学和临床研究人员那里确定新的发展研究项目。此外，根据我们在培养强调翻译研究的新教师方面的良好记录，我们提出了一个有针对性的职业发展计划，以进一步加强孢子学教师的翻译研究干部队伍。这4个孢子翻译研究项目构成了治疗G1癌的新颖的尖端方法，包括以下研究：新的15-PGDH结肠癌抑制途径的预测、预后和治疗应用(项目1，Markowitz和Willson博士)；通过粪便DNA甲基化DNA检测对晚期结肠腺瘤进行无创的早期检测(项目2，Cooper和Li博士)；通过高通量下一代基因组测序对结肠癌基因突变进行全面评估，以预测临床结果(项目3，Willis和Wang博士)；以及食管腺癌易感基因的鉴定(项目4，Chak博士和Elston)。这些项目得益于我们孢子学院开发的特殊人群和科学资源，这些资源用于：结肠癌生物标记物的评估、新药发现的高通量筛查、结肠癌筛查模式的评估、从存档的福尔马林固定组织样本中进行下一代测序以及家族性Barrett‘s和食管腺癌的研究。这些调查人员的实力和他们可支配的资源将确保这一计划取得重要进展。

This Case Gl SPORE proposal provides for a cutting edge Specialized Program of Research Excellence in gastrointestinal malignancies with emphasis on colorectal cancers and with additional attention to adenocarcinoma of the esophagus. This comprehensive program builds on the resources of the Case Comprehensive Cancer Center to propose 4 translational Research Projects to bring new molecular advances to patients with Gl Cancers. A series of 4 core resources support these research projects and also establish a strong programmatic infrastructure for translational research in Gl cancers. We further have developed a comprehensive infrastructure for identifying new Developmental Research Projects from basic science and clinical investigators from across the Case Cancer Center. Moreover, drawing on our strong track record of developing new faculty who emphasize translational research in Gl cancers, we propose a targeted Career Development Program to further enhance the translational research cadre of SPORE faculty. The 4 SPORE translational research projects constitute novel and cutting edge approaches to Gl cancers and include studies of: the predictive, prognostic, and therapeutic applications of the new 15-PGDH colon cancer suppressor pathway (Project 1, Drs. Markowitz and Willson); the noninvasive early detection of advanced colon adenomas through stool DNA testing for methylated DNA (Project 2, Drs. Cooper and Li); the comprehensive evaluation of colon cancer gene mutations as predictors of clinical outcome, via use of high throughput Next Generation genomic sequencing (Project 3, Drs. Willis and Wang); and the identification of esophageal adenocarcinoma susceptibility genes (Project 4, Drs. Chak and Elston). These projects are advantaged by special population and scientific resources developed by our SPORE faculty for: evaluation of colon cancer biomarkers, for high throughput screening for new drug discovery, for evaluation of colon cancer screening modalities, for Next Generation sequencing from archived formalin fixed tissue samples, and for study of familial Barrett's and adenocarcinomas of the esophagus. The strength of these investigators and the resources at their disposal will ensure this program leads to important advances.